NASDAQ · PTCT
Healthcare · Biotechnology
$71.79
Down-$0.39 (-0.54%)
Updated Sep 3, 2026, 10:00 PM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
PTCT closed at $71.79 after 21 trading sessions, up 3.73% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $71.15 | $72.68 | $69.835 | $71.79 | 902.58K |
| Sep 1, 2026 | $69.42 | $70.84 | $69.05 | $70.56 | 691.02K |
| Aug 31, 2026 | $69.98 | $70.42 | $68.755 | $69.54 | 841.1K |
| Aug 28, 2026 | $71.08 | $71.49 | $69.61 | $70.09 | 692.68K |
| Aug 27, 2026 | $72.11 | $72.66 | $70.91 | $71.81 | 746.33K |
| Aug 26, 2026 | $73.18 | $73.525 | $71.81 | $72.69 | 533.67K |
| Aug 25, 2026 | $71.69 | $73.47 | $71.69 | $73.47 | 624.46K |
| Aug 24, 2026 | $69.67 | $71.45 | $68.02 | $71.06 | 897.68K |
| Aug 21, 2026 | $70.54 | $71.36 | $69.79 | $69.82 | 674.74K |
| Aug 20, 2026 | $73.05 | $73.56 | $70.46 | $70.52 | 802.51K |
| Aug 19, 2026 | $73.72 | $74.02 | $72.215 | $73.67 | 1.51M |
| Aug 18, 2026 | $72.86 | $74.03 | $72.225 | $72.63 | 731.63K |
| Aug 17, 2026 | $71.70 | $73.02 | $71.245 | $72.88 | 985.77K |
| Aug 14, 2026 | $71.58 | $72.13 | $70.85 | $71.70 | 564.33K |
| Aug 13, 2026 | $73.14 | $73.335 | $71.69 | $71.97 | 697.35K |
| Aug 12, 2026 | $73.23 | $74.22 | $72.18 | $72.64 | 976.04K |
| Aug 11, 2026 | $75.00 | $75.00 | $72.86 | $73.70 | 763.59K |
| Aug 10, 2026 | $72.77 | $74.75 | $72.475 | $74.63 | 826.18K |
| Aug 7, 2026 | $71.71 | $73.37 | $70.95 | $73.31 | 963.18K |
| Aug 6, 2026 | $68.99 | $71.04 | $68.99 | $70.85 | 928.9K |
| Aug 5, 2026 | $69.21 | $70.19 | $68.495 | $69.21 | 1.1M |
The latest Smart Investors Daily articles mentioning PTCT.
PTCT research
Company profile and research snapshot.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Barclays | Overweight | — |
| Aug 13, 2026 | Wells Fargo | Overweight | — |
| Jul 31, 2026 | Morgan Stanley | Overweight | — |
| Jul 31, 2026 | Wells Fargo | Overweight | — |
| Jul 20, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 24, 2026
The presentations include new data from clinical trials and real-world evidence which reinforce the clinically meaningful benefits of Sephience on lowering phenylalanine (Phe), significant diet liberalization and
SeekingAlpha · Aug 24, 2026
PTC Therapeutics (PTCT) risk-reward: Sephience revenue growth and potential ST-920 Fabry gene therapy FDA approval could lift valuation.
Benzinga · Aug 14, 2026
Barclays analyst Eliana Merle maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $120 to $122.
Benzinga · Aug 13, 2026
PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PTCT.
